Atlas Trials

Alternating Treatment With Fruquintinib and Bevacizumab Plus Capecitabine as Maintenance Therapy After First-Line Treatment in Metastatic Colorectal Cancer

Clinical trial NCT05659290 · UNKNOWN

Trial details

NCT number
NCT05659290
Sponsor
Nanfang Hospital, Southern Medical University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Colorectal Cancer
Start date
2023-01-01
Primary completion
2025-12-01
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.